Elevation of Preoperative s-CEA Concentration in Stage IIA Colorectal Cancer Can Also Be a High Risk Factor for Stage II Patients

被引:29
作者
Kim, Chan Wook [1 ]
Yoon, Yong Sik [1 ]
Park, In Ja [1 ]
Lim, Seok-Byung [1 ]
Yu, Chang Sik [1 ]
Kim, Jin Cheon [1 ]
机构
[1] Univ Ulsan, Coll Med, Dept Surg, Inst Innovat Canc Res,Asan Med Ctr, Seoul, South Korea
关键词
CARCINOEMBRYONIC ANTIGEN LEVEL; COLON-CANCER; ADJUVANT CHEMOTHERAPY; CURATIVE RESECTION; PROGNOSIS; FLUOROURACIL; RECURRENCE; NUMBER; RECOMMENDATIONS; OXALIPLATIN;
D O I
10.1245/s10434-013-2919-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate stage IIA colorectal cancer in terms of recurrence so as to discover whether high preoperative serum carcinoembryonic antigen (s-CEA) levels indicate that the patient should be included in a high-risk group in stage II colorectal cancer. We retrospectively reviewed the records of 1543 patients with stage IIA colorectal cancer who underwent curative surgery between January 2000 and December 2007. The 5-year disease-free survival and overall survival rates were significantly lower in patients with a higher than normal preoperative s-CEA (90.5 % vs. 82.5 %, P < 0.001, and 92.4 % vs. 87.8 %, P = 0.034, respectively). Multivariate analysis revealed that elevated preoperative s-CEA level, preoperative obstruction, rectal cancer, and dissection of fewer than 12 nodes were independent statistically significant prognostic factors that predicted disease-free survival in patients with stage IIA disease after curative resection. Elevated preoperative s-CEA concentration is a reliable predictor of recurrence after curative resection in patients with stage IIA colorectal cancer. Patients with stage IIA disease with elevated preoperative s-CEA level do worse than those with normal levels and might constitute a group to evaluate for adjuvant chemotherapy. Further studies on the effect of adjuvant chemotherapy in this group are needed.
引用
收藏
页码:2914 / 2920
页数:7
相关论文
共 24 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]  
[Anonymous], JAMA
[3]  
BEAUDONNET A, 1981, CLIN CHEM, V27, P771
[4]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[5]   Obstruction and perforation in colorectal adenocarcinoma: An analysis of prognosis and current trends [J].
Chen, HS ;
Sheen-Chen, SM .
SURGERY, 2000, 127 (04) :370-376
[6]  
Compton CC, 2000, ARCH PATHOL LAB MED, V124, P979
[7]  
Duffy MJ, 2001, CLIN CHEM, V47, P624
[8]  
HERBETH B, 1980, ONCODEV BIOL MED, V1, P191
[9]  
Holt A, 2010, AM SURGEON, V76, P1100
[10]   Preoperative Carcinoembryonic Antigen Level as an Independent Prognostic Factor in Potentially Curative Colon Cancer [J].
Huh, Jung Wook ;
Oh, Byung Ryul ;
Kim, Hyeong Rok ;
Kim, Young Jin .
JOURNAL OF SURGICAL ONCOLOGY, 2010, 101 (05) :396-400